Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
In this study, researchers are assessing a new way to determine the best dosing of fludarabine. The people in this study are children and young adults getting CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). Their cancer has come back or keeps growing despite treatment. They will be getting a CAR T-cell therapy called tisagenlecleucel (Kymriah).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
This study is assessing a blood test that may tell doctors which people need immunotherapy after bladder cancer surgery. Many types of tumors lose cells into the bloodstream and shed their DNA. This circulating tumor DNA (ctDNA) may be found before changes in a tumor can be seen on scans.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here for Substudy 01A or here for Substudy 01C to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if adding autogene cevumeran to nivolumab is better than nivolumab alone to treat urothelial (bladder) cancer. The people in this study have muscle-invasive urothelial cancer (MIUC) that has been removed with surgery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Venetoclax blocks Bcl-2, a protein that helps cancer cells survive and resist the effects of anti-cancer treatments. By blocking Bcl-2, venetoclax may cause the death of cancer cells or make them more sensitive to other treatments. It is taken orally (by mouth).
Researchers want to find the best dose of ELA026 to use in people with secondary hemophagocytic lymphohistiocytosis (sHLH). When you have sHLH, certain white blood cells become overactive and attack other healthy blood cells. The white blood cells damage your own healthy tissues and organs. sHLH is usually triggered by another disease, such as cancer, infection, or autoimmune disease.
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
